Timeline of key progresses in ER-, Bcr-Abl-, EGFR-, HER2- and Akt-targeted cancer therapy. Based on the identification of ER, Bcr-Abl, EGFR, HER2 and Akt in promoting tumorigenesis, ER-, Bcr-Abl-, EGFR- and HER2-targeted therapy have been approved for treating various types of cancer,...
AKT2S128/CCTαS315/319/323-positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs) Jie Chen Lingyuan Zhang Qimin Zhan Signal Transduction and Targeted Therapy(2024) ...
Dysregulation of immune checkpoints is a protective mechanism used by a number of malignancies to escape from the immune surveillance allowing for cancer development [1]. This has inspired the idea of boosting the host immune response as an anti-cancer therapy. Indeed, the blockage of immune chec...
For over three decades, a mainstay and goal of clinical oncology has been the development of therapies promoting the effective elimination of cancer cells by apoptosis. This programmed cell death process is mediated by several signalling pathways (referr
This is particularly true for tumors driven by cancer stem cells (CSCs), which have been shown to be responsible for tumor heterogeneity, metastasis, chemoresistance, and tumor relapse in a large number of cancers [1,2,3,4]. Thus, from a medicinal perspective, targeting the CSC population ...
recurrent breast cancerHeterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells for omnidirectional ...
Radiotherapy (RT) is the most effective cytotoxic therapy for localized solid carcinomas and is widely used in current clinical cancer treatments. Statistics indicate that approximately 60% of cancer patients in the United States receive radical RT during treatment [1,2]. The therapeutic principle of...
John Wiley & Sons, LtdThoracic CancerDamania B. Targeting the PI3K/Akt/mTOR pathway in AIDS-associ- ated malignancies. In: Dittmer DP, Krown SE, editors. Molecular basis for therapy of AIDS-defining cancers. New York: Springer; 2010. p. 152-66....
A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550–562 (2009). Article CAS Google Scholar Garcia-Echeverria, C. & Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511–5526 (2008). ...
Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including disease initiation, maintenance and therapy resistance. As a result, there have been advances in the development and evaluation of epigenetic therapies for cancer, revealing substantial promise but also challenges. Three...